Human genetics of metabolic dysfunction–associated steatotic liver disease: from variants to cause to precision treatment
Journal of Clinical Investigation · 01.04.2025 · 135 (7)
DOI: 10.1172/jci186424 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.04.2025. Verfasst von Vincent L Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Fatty Liver, Membrane Proteins, Precision Medicine, Gene-Environment Interaction. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Metabolic dysfunction–associated steatotic liver disease (MASLD) is characterized by increased hepatic steatosis with cardiometabolic disease and is a leading cause of advanced liver disease. We review here the genetic basis of MASLD. The genetic variants most consistently associated with hepatic steatosis implicate genes involved in lipoprotein input or output, glucose metabolism, adiposity/fat distribution, insulin resistance, or mitochondrial/ER biology. The distinct mechanisms by which these variants promote hepatic steatosis result in distinct effects on cardiometabolic disease that may be best suited to precision medicine. Recent work on gene-environment interactions has shown that genetic risk is not fixed and may be exacerbated or attenuated by modifiable (diet, exercise, alcohol intake) and nonmodifiable environmental risk factors. Some steatosis-associated variants, notably those in patatin-like phospholipase domain-containing 3 ( PNPLA3 ) and transmembrane 6 superfamily member 2 ( TM6SF2 ), are associated with risk of developing adverse liver-related outcomes and provide information beyond clinical risk stratification tools, especially in individuals at intermediate to high risk for disease. Future work to better characterize disease heterogeneity by combining genetics with clinical risk factors to holistically predict risk and develop therapies based on genetic risk is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Chen, V. L., Kuppa, A., Oliveri, A., Chen, Y., Ponnandy, P., Patel, P. B., Palmer, N. D., & Speliotes, E. K. (2025). Human genetics of metabolic dysfunction–associated steatotic liver disease: from variants to cause to precision treatment. Journal of Clinical Investigation, 135(7). https://doi.org/10.1172/jci186424
Vancouver
Chen VL, Kuppa A, Oliveri A, Chen Y, Ponnandy P, Patel PB, et al. Human genetics of metabolic dysfunction–associated steatotic liver disease: from variants to cause to precision treatment. Journal of Clinical Investigation. 2025;135(7). doi:10.1172/jci186424
BibTeX
@article{Chen2025,
author = {Chen, Vincent L and Kuppa, Annapurna and Oliveri, Antonino and Chen, Yanhua and Ponnandy, Prabhu and Patel, Puja B and Palmer, Nicholette D and Speliotes, Elizabeth K},
title = {Human genetics of metabolic dysfunction–associated steatotic liver disease: from variants to cause to precision treatment},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {7},
doi = {10.1172/jci186424}
}
EUVIMED